A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis
In this trial involving individuals with anti-CCP3 levels ≥2 times the ULN, 12 months of HCQ did not prevent the development of clinical RA at 36 months.
Authors
- Athan Tiliakos (ORCID: https://orcid.org/0009-0002-5521-6020)
- Elena Schiopu (ORCID: https://orcid.org/0000-0002-1831-5292)
- Diane Horowitz
- Kevin D. Deane (ORCID: https://orcid.org/0000-0003-2211-4861)
- Maureen McMahon (ORCID: https://orcid.org/0000-0002-2910-7640)
- Ashley Frazer‐Abel
- Jeffrey A. Sparks (ORCID: https://orcid.org/0000-0002-5556-4618)
- David A. Fox (ORCID: https://orcid.org/0000-0002-0230-6607)
- Jonathan Kay (ORCID: https://orcid.org/0000-0002-8970-4260)
- Chelsie Fleischer (ORCID: https://orcid.org/0000-0001-5706-7618)
- Cristina Arriens (ORCID: https://orcid.org/0000-0002-9546-1664)
- Joel M. Guthridge (ORCID: https://orcid.org/0000-0002-9308-237X)
- V. Michael Holers (ORCID: https://orcid.org/0000-0002-5634-7746)
- M. Kristen Demoruelle (ORCID: https://orcid.org/0000-0002-2563-5155)
- Christopher C. Striebich (ORCID: https://orcid.org/0000-0003-2582-7752)
- Jonathan Graf (ORCID: https://orcid.org/0000-0001-5204-9015)
- John M. Davis (ORCID: https://orcid.org/0000-0002-9710-8143)
- Kate York
- Melissa E. Greenleaf
- E. Blair Solow (ORCID: https://orcid.org/0000-0002-4947-2741)
- Elizabeth A. Bemis (ORCID: https://orcid.org/0000-0002-3556-3175)
- Sarah Walker (ORCID: https://orcid.org/0000-0003-4904-4226)
- Lindsy Forbess
- Janel Fedler (ORCID: https://orcid.org/0000-0002-2361-6604)
- Marie L. Feser (ORCID: https://orcid.org/0009-0003-0598-853X)
- Maria I. Danila (ORCID: https://orcid.org/0000-0001-9246-6200)
- Ted R. Mikuls (ORCID: https://orcid.org/0000-0002-0897-2272)
- C. Strickland (ORCID: https://orcid.org/0000-0002-3778-8845)
- Judith A. James (ORCID: https://orcid.org/0000-0002-9574-7355)
- Jennifer M. Grossman
- James R. O’Dell
- Lynette Keyes‐Elstein
- M. Byron
- Ellen Goldmuntz
Institutions
- Cedars-Sinai Medical Center (US)
- Brigham and Women's Hospital (US)
- National Institutes of Health (US)
- Northwell Health (US)
- Feinstein Institute for Medical Research (US)
- Mayo Clinic (US)
- Harvard University (US)
- Emory University (US)
- University of California, Los Angeles (US)
- University of Massachusetts Chan Medical School (US)
- University of California, San Francisco (US)
- Augusta University (US)
- University of Michigan (US)
- University of California System (US)
- Oklahoma Medical Research Foundation (US)
- University of Alabama at Birmingham (US)
- National Institute of Allergy and Infectious Diseases (US)
- Mayo Clinic in Florida (US)
- Rho (United States) (US)
- Anstalt für Verbrennungskraftmaschinen List (Austria) (AT)
- University of Colorado Anschutz Medical Campus (US)
- University of Nebraska Medical Center (US)
- University of San Francisco (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Arthritis & Rheumatology
- Published
- 2025-08-30
- DOI
- https://doi.org/10.1002/art.43366
- Citations
- 12
- Primary Topic
- Drug-Induced Ocular Toxicity
- Type
- article
- Field-Weighted Citation Impact
- 20.48
Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases